产品名称
甘氨酸, United States Pharmacopeia (USP) Reference Standard
SMILES string
NCC(O)=O
InChI key
DHMQDGOQFOQNFH-UHFFFAOYSA-N
InChI
1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)
grade
pharmaceutical primary standard
API family
glycine
manufacturer/tradename
USP
pH
4(0.2 molar aqueous solution)
pKa (25 °C)
(1) 2.35, (2) 9.60
2.35
mp
240 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
脊髓中的抑制性神经递质，NMDA受体的变构调节器。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Glycine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Glycine Irrigation
- Theophylline Sodium Glycinate
- Glycyl-l-tyrosine
- Glycyl-l-glutamine
- Pyrroloquinoline Quinone Disodium
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
存储类别
13 - Non Combustible Solids
wgk
WGK 1
Theophylline Sodium Glycinate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 4333-4333 (2020)
Glycine
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 38(6), 6082-6082 (2018)
Glycyl-l-tyrosine
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 39(4), 5059-5059 (2020)
Pierre Chue
Current pharmaceutical design, 19(7), 1311-1320 (2012-12-01)
Primary negative symptoms (affective flattening or blunting, alogia, avolition) are prominent in approximately 20% of individuals suffering from schizophrenia. These symptoms are particularly associated with impaired functional outcome and poor prognosis. This is in part due to the lack of
Alexander Carvajal-González et al.
Brain : a journal of neurology, 137(Pt 8), 2178-2192 (2014-06-22)
The clinical associations of glycine receptor antibodies have not yet been described fully. We identified prospectively 52 antibody-positive patients and collated their clinical features, investigations and immunotherapy responses. Serum glycine receptor antibody endpoint titres ranged from 1:20 to 1:60 000.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持